S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
T   37.75 (+0.40%)
F   8.89 (+2.07%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
T   37.75 (+0.40%)
F   8.89 (+2.07%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
T   37.75 (+0.40%)
F   8.89 (+2.07%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
T   37.75 (+0.40%)
F   8.89 (+2.07%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
Log in

InMode Stock Price, Forecast & Analysis (NASDAQ:INMD)

$41.55
-5.11 (-10.95 %)
(As of 11/22/2019 04:00 PM ET)
Today's Range
$40.30
Now: $41.55
$45.74
50-Day Range
$21.93
MA: $33.31
$55.66
52-Week Range
$13.06
Now: $41.55
$58.76
Volume2.07 million shs
Average Volume1.13 million shs
Market Capitalization$1.33 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company offers minimally-invasive aesthetic medical products for procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. InMode Ltd. offers its products directly in the United States, Canada, the United Kingdom, Spain, and India, as well as indirectly through third-party distributors internationally. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INMD
CUSIPN/A
Phone972-4909-6313

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$100.16 million
Book Value$5.02 per share

Profitability

Net Income$22.37 million

Miscellaneous

Employees198
Market Cap$1.33 billion
Next Earnings Date2/4/2020 (Estimated)
OptionableNot Optionable

Receive INMD News and Ratings via Email

Sign-up to receive the latest news and ratings for INMD and its competitors with MarketBeat's FREE daily newsletter.


InMode (NASDAQ:INMD) Frequently Asked Questions

What is InMode's stock symbol?

InMode trades on the NASDAQ under the ticker symbol "INMD."

How were InMode's earnings last quarter?

InMode Ltd. (NASDAQ:INMD) issued its quarterly earnings data on Tuesday, November, 5th. The healthcare company reported $0.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.29 by $0.13. The healthcare company had revenue of $40.01 million for the quarter, compared to the consensus estimate of $35.74 million. InMode had a return on equity of 50.50% and a net margin of 30.33%. The company's quarterly revenue was up 57.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.26 earnings per share. View InMode's Earnings History.

When is InMode's next earnings date?

InMode is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for InMode.

What price target have analysts set for INMD?

4 equities research analysts have issued 1 year price objectives for InMode's stock. Their forecasts range from $28.00 to $45.00. On average, they expect InMode's share price to reach $37.00 in the next year. This suggests that the stock has a possible downside of 11.0%. View Analyst Price Targets for InMode.

What is the consensus analysts' recommendation for InMode?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InMode in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for InMode.

Has InMode been receiving favorable news coverage?

News headlines about INMD stock have been trending somewhat negative this week, according to InfoTrie. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. InMode earned a media sentiment score of -1.9 on InfoTrie's scale. They also gave media coverage about the healthcare company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for InMode.

Who are some of InMode's key competitors?

What other stocks do shareholders of InMode own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InMode investors own include NVIDIA (NVDA), Trade Desk (TTD), salesforce.com (CRM), Zscaler (ZS), Twilio (TWLO), Amarin (AMRN), Crowdstrike (CRWD), Docusign (DOCU), Roku (ROKU) and Alibaba Group (BABA).

Who are InMode's key executives?

InMode's management team includes the folowing people:
  • Mr. Moshe Mizrahy, Chairman & CEO (Age 66)
  • Mr. Yair Malca, Chief Financial Officer (Age 41)
  • Dr. Michael Kreindel, CTO & Director (Age 51)
  • Mr. Shakil Lakhani, Pres of North America (Age 35)
  • Dr. Spero Theodorou, Chief Medical Officer (Age 47)

When did InMode IPO?

(INMD) raised $75 million in an initial public offering on Thursday, August 8th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. ​Barclays, UBS Investment Bank and Canaccord Genuity served as the underwriters for the IPO and Baird was co-manager.

When does the company's lock-up period expire?

InMode's lock-up period expires on Tuesday, February 4th. InMode had issued 5,000,000 shares in its IPO on August 8th. The total size of the offering was $70,000,000 based on an initial share price of $14.00. After the end of the company's lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Who are InMode's major shareholders?

InMode's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Rice Hall James & Associates LLC (0.18%), Dean Capital Investments Management LLC (0.14%), Emerald Advisers LLC (0.08%), Alpine Woods Capital Investors LLC (0.06%), D.A. Davidson & CO. (0.04%) and Steward Partners Investment Advisory LLC (0.02%).

Which institutional investors are buying InMode stock?

INMD stock was purchased by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Dean Capital Investments Management LLC, Emerald Advisers LLC, Alpine Woods Capital Investors LLC, D.A. Davidson & CO., Steward Partners Investment Advisory LLC, Tower Research Capital LLC TRC and Patriot Financial Group Insurance Agency LLC.

How do I buy shares of InMode?

Shares of INMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is InMode's stock price today?

One share of INMD stock can currently be purchased for approximately $41.55.

How big of a company is InMode?

InMode has a market capitalization of $1.33 billion and generates $100.16 million in revenue each year. InMode employs 198 workers across the globe.View Additional Information About InMode.

What is InMode's official website?

The official website for InMode is http://www.inmodemd.com/.

How can I contact InMode?

InMode's mailing address is TAVOR BUILDING SHAAR YOKNEAM POB 533, YOKNEAM L3, 2069200. The healthcare company can be reached via phone at 972-4909-6313 or via email at [email protected]


MarketBeat Community Rating for InMode (NASDAQ INMD)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  55 (Vote Outperform)
Underperform Votes:  31 (Vote Underperform)
Total Votes:  86
MarketBeat's community ratings are surveys of what our community members think about InMode and other stocks. Vote "Outperform" if you believe INMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel